Ascletis Reports Preclinical Weight-Loss Data
Ascletis announced preclinical study results for ASC36_35FDC, indicating potential for convenient once-monthly to once-quarterly dosing and significant weight loss. The data was presented at EASD 2026.
Ascletis announced preclinical study results for ASC36_35FDC, indicating potential for convenient once-monthly to once-quarterly dosing and significant weight loss. The data was presented at EASD 2026.